Version 10/25/21 (Add. #3)

NCI National Clinical Trials Network

EA6192/PET-Stop

For Patients with Advanced Melanoma

EA6192 Available Through ECOG-ACRIN Cancer Research Group

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

Patient Population

See Section 3.0 for Complete Eligibility Details

Step 0 Pre-registration Eligibility Criteria:

- Age ≥18 years, ECOG PS 0-2, and adequate lab values
- Must have active advanced melanoma, defined as unresectable stage IIIB-IV (AJCC 8); exception per protocol
- Must have melanoma originating from cutaneous, acral-lentiginous, or mucosal primary sites (ocular primary site is not eligible; unknown primary site is eligible)
- Must have had measurable disease (imRECIST) prior to start of initial anti-PD-1 therapy, defined per protocol
- Must be actively receiving standard of care anti-PD-1 therapy, currently be 52 weeks (+/- 2 weeks) from start of anti-PD-1 therapy, and have not experienced a toxicity that prevents them from continuing (see protocol for permitted systemic anti-PD-1 therapy regimens)
- Must not be receiving concurrent anti-tumor therapies in addition to the standard of care anti-PD-1 regimens (patients receiving bisphosphonates and RANKL inhibitors for management of bone metastases are eligible)
- HIV/HBV/HCV patients are eligible per protocol
- Patients with brain metastases are eligible per protocol
- Patients with known history/current symptoms of cardiac disease, or history of treatment with cardiotoxic agents should be NYHA class 2B or better
- Must have experienced complete/partial response, or stable disease on restaging CT scans (imRECIST) that is maintained on diagnostic restaging CT scan at week 48 (+/- 6 weeks) from start of initial anti-PD-1 therapy

Step 1 Registration Eligibility Criteria:

- Must register within 4 weeks of registration to Step 0, and meet one of: 1) Had no positive hypermetabolic lesions on week 52 PDG-PET/CT 2) if positive, either a representative lesion was biopsied within 14 days of Step 0 registration and subsequent pathology determines the presence/absence of viable tumor, OR documentation states the patient is not able to undergo biopsy

Treatment Plan

See Section 5.0 for Complete Treatment Details

Prior to Step 0 registration, patient must have been actively receiving standard of care anti-PD-1 therapy. All enrolled patients will continue their standard of care anti-PD-1 therapy through 52 weeks (+/- 2 weeks) from start of initial anti-PD-1 therapy, then proceed to Arm A or B:

Arm A– Negative FDG-PET/CT scan or positive FDG-PET/CT scan, but negative biopsy for viable tumor:

- Patients will discontinue their anti-PD-1 therapy after week 52 (+/- 2 weeks) from start of initial anti-PD-1 therapy and be monitored by active surveillance

Arm B– Positive FDG-PET/CT scan and positive biopsy for viable tumor (or biopsy not performed):

- Patients will continue their anti-PD-1 therapy for an additional 48 weeks beyond week 52 (+/- 2 weeks) from the start of initial anti-PD-1 therapy, with one of the standard FDA approved regimens
  - ◊ Nivolumab 240 mg IV Q2 weeks or 480 mg IV Q 4 weeks
  - ◊ Pembrolizumab 200 mg IV Q 3 weeks or 400 mg IV Q 6 weeks
- If patients experience toxicities, management will follow standard of care algorithms based on package inserts
- If disease progression or dose limiting toxicity is not experienced, patients will continue on anti-PD-1 therapy for 2 years total treatment, then discontinue anti-PD-1 and undergo FDG-PET/CT scan
- A biopsy and local pathologic assessment of the tissue will be performed if there is remaining hypermetabolic lesion(s), if the patient is able

If patients experience disease progression (either arm), therapeutic management will be at the discretion of the treating physician

Study Chair:
Geoffrey T. Gibney, MD

Study Co-Chair:
Michael B. Atkins, MD

Patient Enrollment

All Sites: Oncology Patient Enrollment Network (OPEN), https://open.ctsu.org

Protocol Information

ECOG-ACRIN Operations-Boston: 857-504-2900, http://ecog-acrin.org (Member Login)

Please Enroll Your Eligible Patients!

ECOG-ACRIN cancer research group

EA6192

Schema



1. Patient must be actively receiving standard of care anti-PD-1 therapy and currently be 52 weeks (+/- 2 weeks) from start of anti-PD-1 therapy at the time of step 0 pre-registration.